CAIX-targeted PET/CT scans for detecting solid tumors in adults
Tests a scan using 68Ga-CAIX to find solid tumors in adults.
Plain-language title generated from the registry record
Registry title: CAIX-targeted PET/CT in Solid Tumors
Key facts
- Where
- Wuhan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected or confirmed solid tumors to have a CAIX-targeted PET/CT scan.
- Age
- 18 years and above
- Sex
- Men and women can join
- Disease stage
- Suspected malignant solid tumor, or newly diagnosed or recurrent/metastatic solid tumor confirmed by histopathology
Main reasons for not taking part
- Severe liver, kidney or heart problems
- Cannot have a PET scan (for example severe obesity or claustrophobia)
- Pregnant or breastfeeding women
- Other reasons the researchers decide and document
Read by machine on 12 November 2026.
Where in China
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaContact: Lei Zheng, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zhongnan Hospital
- Trial code
- NCT07833085
- Record updated
- 13 October 2026
- Original description
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.Read full original descriptionShow less
Carbonic Anhydrase IX-targeted PET/CT Imaging for Detecting Solid Tumors
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.
Inclusion: Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; Age of 18 years and above, both male and female are eligible; The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol.
Exclusion: Participants with severe liver and kidney dysfunction and cardiac dysfunction; Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; Pregnant or lactating women; Other situations that researchers believe should be excluded and documented.